Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
Sagebrush Gold Ltd. (NASDAQ: SAGE) Delayed: 8.68 --0 (-0%)
Previous Close $8.68    52 Week High $62.64 
Open $8.68    52 Week Low $26.28 
Day High $8.68    P/E N/A 
Day Low $8.68    EPS $-0.94 
Volume 333,870